Adverse effects of drugs in the treatment of viral hepatitis

被引：43

作者：

Negro, Francesco ^{[1
,2
,3
]}

机构：

[1] Univ Hosp Geneva, Div Clin Pathol, CH-1211 Geneva 14, Switzerland

[2] Univ Hosp Geneva, Div Gastroenterol, CH-1211 Geneva 14, Switzerland

[3] Univ Hosp Geneva, Div Hepatol, CH-1211 Geneva 14, Switzerland

来源：

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY | 2010年 / 24卷 / 02期

关键词：

Hepatitis B virus; Hepatitis C virus; Interferon-alpha; Side effects; Barriers to treatment; ALPHA-2A PLUS RIBAVIRIN; INHIBITOR DEBIO 025; C VIRUS-INFECTION; INTERFERON-ALPHA; THERAPY; PEGINTERFERON; GENOTYPE-1; ANEMIA; THROMBOCYTOPENIA; COMBINATION;

D O I：

10.1016/j.bpg.2009.10.012

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The hepatitis B virus (HBV) and the hepatitis C virus (HCV) affect approximately 400-500 million individuals worldwide. Both infections are characterised by a significant morbidity and mortality: chronic hepatitis B and C may evolve towards the development of cirrhosis and primary hepatocellular carcinoma. During the last two decades, several new antivirals have been developed that are active against HBV and HCV, allowing sustained cure rates in a significant proportion of patients. All these drugs have side effects, which may represent a major barrier to achieve cure in many patients in need. I will review the most common adverse events reported during the therapy of chronic hepatitis B and C, with some recommendations for proper management. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：183 / 192

页数：10

共 47 条

[1] Predictors of response of US veterans to treatment for the hepatitis C virus [J].

Backus, Lisa I. ;

Boothroyd, Derek B. ;

Phillips, Barbara R. ;

Mole, Larry A. .

HEPATOLOGY, 2007, 46 (01) :37-47

[2] Dermatologic disorders associated with chronic hepatitis C: Effect of interferon therapy [J].

Berk, David R. ;

Bayliss Mallory, Susan ;

Keeffe, Emmet B. ;

Ahmed, Aijaz .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (02) :142-151

[3]

Crabbé R, 2009, EXPERT OPIN INV DRUG, V18, P211, DOI [10.1517/13543780802651583 , 10.1517/13543780802651583]

[4] Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage [J].

De Franceschi, L ;

Fattovich, G ;

Turrini, F ;

Ayi, K ;

Brugnara, C ;

Manzato, F ;

Noventa, F ;

Stanzial, AM ;

Solero, P ;

Corrocher, R .

HEPATOLOGY, 2000, 31 (04) :997-1004

[5] Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy [J].

Del Rio, Richard A. ;

Post, Anthony B. ;

Singer, Mendel E. .

HEPATOLOGY, 2006, 44 (06) :1598-1606

[6] Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients [J].

Dereure, O ;

Raison-Peyron, N ;

Larrey, D ;

Blanc, F ;

Guilhou, JJ .

BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (06) :1142-1146

[7] Cutaneous side effects of alpha interferon [J].

Descamps, V .

PRESSE MEDICALE, 2005, 34 (21) :1668-1672

[8] Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy [J].

Deutsch, M ;

Dourakis, S ;

Manesis, EK ;

Gioustozi, A ;

Hess, G ;

Horsch, A ;

Hadziyannis, S .

HEPATOLOGY, 1997, 26 (01) :206-210

[9] Suicidal ideation during interferon-α2b and ribavirin treatment of patients with chronic hepatitis C [J].

Dieperink, E ;

Ho, SB ;

Tetrick, L ;

Thuras, P ;

Dua, K ;

Willenbring, ML .

GENERAL HOSPITAL PSYCHIATRY, 2004, 26 (03) :237-240

[10] Immune thrombocytopenia and alpha-interferon therapy [J].

Dourakis, SP ;

Deutsch, M ;

Hadziyannis, SJ .

JOURNAL OF HEPATOLOGY, 1996, 25 (06) :972-975

← 1 2 3 4 5 →